Adverse events of interest
| . | ZUMA-7 . | Belinda . | Transform . | |||
|---|---|---|---|---|---|---|
| Axi-cel . | SOC . | Tisa-cel . | SOC . | Liso-cel . | SOC . | |
| CRS, any grade (%) | 92 | — | 61 | — | 49 | — |
| CRS, grade ≥3 (%) | 6 | — | 5 | — | 1 | — |
| Neurologic toxicity, any grade (%) | 60 | — | 10 | — | 12 | — |
| Neurologic toxicity, grade ≥3 (%) | 21 | — | 2 | — | 4 | — |
| Tocilizumab use (%) | 65 | — | 32 | — | 24 | — |
| Corticosteroid usage for toxicity management (%) | 24 | — | 10 | — | 17 | — |
| Anemia, grade ≥3 (%) | 30 | 39 | 33 | 58 | 49 | 49 |
| Thrombocytopenia, grade ≥3 (%) | 15 | 57 | 32 | 48 | 49 | 64 |
| Neutropenia, grade ≥3 (%) | 69 | 41 | 40 | 39 | 80 | 51 |
| Febrile neutropenia, grade ≥3 (%) | 2 | 27 | 13 | 25 | 15 | 24 |
| Fatigue, any grade (%) | 42 | 52 | 24 | 31 | 39 | 38 |
| Nausea, any grade (%) | 41 | 69 | 41 | 49 | 53 | 57 |
| . | ZUMA-7 . | Belinda . | Transform . | |||
|---|---|---|---|---|---|---|
| Axi-cel . | SOC . | Tisa-cel . | SOC . | Liso-cel . | SOC . | |
| CRS, any grade (%) | 92 | — | 61 | — | 49 | — |
| CRS, grade ≥3 (%) | 6 | — | 5 | — | 1 | — |
| Neurologic toxicity, any grade (%) | 60 | — | 10 | — | 12 | — |
| Neurologic toxicity, grade ≥3 (%) | 21 | — | 2 | — | 4 | — |
| Tocilizumab use (%) | 65 | — | 32 | — | 24 | — |
| Corticosteroid usage for toxicity management (%) | 24 | — | 10 | — | 17 | — |
| Anemia, grade ≥3 (%) | 30 | 39 | 33 | 58 | 49 | 49 |
| Thrombocytopenia, grade ≥3 (%) | 15 | 57 | 32 | 48 | 49 | 64 |
| Neutropenia, grade ≥3 (%) | 69 | 41 | 40 | 39 | 80 | 51 |
| Febrile neutropenia, grade ≥3 (%) | 2 | 27 | 13 | 25 | 15 | 24 |
| Fatigue, any grade (%) | 42 | 52 | 24 | 31 | 39 | 38 |
| Nausea, any grade (%) | 41 | 69 | 41 | 49 | 53 | 57 |
SOC, standard of care.